MX369259B - Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). - Google Patents
Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).Info
- Publication number
- MX369259B MX369259B MX2015015009A MX2015015009A MX369259B MX 369259 B MX369259 B MX 369259B MX 2015015009 A MX2015015009 A MX 2015015009A MX 2015015009 A MX2015015009 A MX 2015015009A MX 369259 B MX369259 B MX 369259B
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- compounds
- oral dosing
- oral
- dosing
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición sólida que comprende una péptido GLP-1 y un potenciador para usarse como un medicamento por administración oral, en donde a) el péptido tiene vida media plasmática en humanos al menos de 60 horas; b) la composición se administra al menos 3 veces; y c) la composición se administra tal que la relación entre la vida media plasmática en días en humanos del péptido y el intervalo de dosificación en días de la composición es mayor de 2:1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13166205 | 2013-05-02 | ||
| PCT/EP2014/058974 WO2014177683A1 (en) | 2013-05-02 | 2014-05-02 | Oral dosing of glp-1 compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015009A MX2015015009A (es) | 2016-03-09 |
| MX369259B true MX369259B (es) | 2019-11-04 |
Family
ID=48190381
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015009A MX369259B (es) | 2013-05-02 | 2014-05-02 | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
| MX2018012166A MX2018012166A (es) | 2013-05-02 | 2015-10-27 | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
| MX2019013123A MX2019013123A (es) | 2013-05-02 | 2015-10-27 | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012166A MX2018012166A (es) | 2013-05-02 | 2015-10-27 | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
| MX2019013123A MX2019013123A (es) | 2013-05-02 | 2015-10-27 | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20160067184A1 (es) |
| EP (2) | EP3485900A1 (es) |
| JP (2) | JP6672140B2 (es) |
| KR (3) | KR20180115814A (es) |
| AU (1) | AU2014261336B2 (es) |
| BR (1) | BR112015026325A2 (es) |
| CA (1) | CA2910903A1 (es) |
| CY (1) | CY1120730T1 (es) |
| DK (1) | DK2991671T3 (es) |
| ES (1) | ES2688462T3 (es) |
| HR (1) | HRP20181393T1 (es) |
| HU (1) | HUE040609T2 (es) |
| IL (1) | IL241813A (es) |
| LT (1) | LT2991671T (es) |
| MX (3) | MX369259B (es) |
| MY (1) | MY172578A (es) |
| PL (1) | PL2991671T3 (es) |
| PT (1) | PT2991671T (es) |
| RS (1) | RS58039B1 (es) |
| RU (1) | RU2671406C2 (es) |
| SA (1) | SA515370075B1 (es) |
| SI (1) | SI2991671T1 (es) |
| WO (1) | WO2014177683A1 (es) |
| ZA (2) | ZA201507096B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| PT2696687T (pt) | 2011-04-12 | 2017-02-02 | Novo Nordisk As | Derivados de glp-1 duplamente acilados |
| ES2690553T3 (es) | 2012-03-22 | 2018-11-21 | Novo Nordisk A/S | Composiciones de péptidos GLP-1 y preparación de estas |
| JP6356660B2 (ja) | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー／エス | 送達剤を含む組成物およびその調製 |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | 包含肽和递送剂的片剂制剂 |
| MX369259B (es) | 2013-05-02 | 2019-11-04 | Novo Nordisk As | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
| KR102294577B1 (ko) | 2015-01-12 | 2021-08-26 | 엔터리스 바이오파마, 인크. | 고체 경구 제형 |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| US11196462B2 (en) | 2016-02-22 | 2021-12-07 | Qualcomm Incorporated | Multi-layer beamforming in millimeter-wave multiple-input/multiple-output systems |
| PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
| SG11202002841PA (en) * | 2017-10-12 | 2020-04-29 | Novo Nordisk As | Semaglutide in medical therapy |
| MX2020004497A (es) * | 2017-10-31 | 2020-08-13 | Medimmune Ltd | Administracion oral de analogos del peptido glp-1. |
| ES2960687T3 (es) | 2018-02-02 | 2024-03-06 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CA3107345A1 (en) | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Gip/glp1 co-agonist compounds |
| US11471512B2 (en) * | 2019-03-01 | 2022-10-18 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of a peptide |
| WO2021089752A1 (en) | 2019-11-07 | 2021-05-14 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| TW202140063A (zh) | 2020-02-18 | 2021-11-01 | 丹麥商諾佛 儂迪克股份有限公司 | 醫藥配方 |
| EP4142695A1 (en) | 2020-04-29 | 2023-03-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
| JP2023534130A (ja) * | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
| BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
| EP4360645A1 (en) * | 2021-06-25 | 2024-05-01 | Gan & Lee Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing glp-1 compound |
| KR20230010571A (ko) | 2021-07-12 | 2023-01-19 | 한미약품 주식회사 | Glp-1 유사체를 함유하는 경구 투여 제형 조성물 |
| KR20240036563A (ko) | 2021-07-15 | 2024-03-20 | 노보 노르디스크 에이/에스 | N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제 |
| WO2023065231A1 (en) * | 2021-10-21 | 2023-04-27 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
| WO2023123063A1 (en) * | 2021-12-29 | 2023-07-06 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| KR20230132256A (ko) | 2022-03-08 | 2023-09-15 | 이정열 | 오징어 조획장치 |
| KR20230147981A (ko) | 2022-04-15 | 2023-10-24 | 이정열 | 어류 탈취기 |
| KR20230167546A (ko) | 2022-06-02 | 2023-12-11 | 이정열 | 어류 탈취기 |
| KR20240018118A (ko) | 2022-08-02 | 2024-02-13 | 이정열 | 어류 탈취기 |
| WO2024040356A1 (en) * | 2022-08-25 | 2024-02-29 | The University Of British Columbia | Mucoadhesive pharmaceutical dosage form for unidirectional release of peptide therapeutic particles |
| KR20240055265A (ko) | 2022-10-20 | 2024-04-29 | 이정열 | 어류 탈취기 |
| WO2024110614A1 (en) * | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
| WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| EP1149066B1 (en) | 1999-02-05 | 2005-11-09 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| AU775063C (en) | 1999-04-30 | 2005-05-12 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| AU2002228608A1 (en) | 2000-12-13 | 2002-06-24 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| CN1501809B (zh) * | 2000-12-13 | 2012-10-10 | 伊莱利利公司 | 应用胰高血糖素样促胰岛肽的长期治疗方案 |
| PL209734B1 (pl) | 2002-02-20 | 2011-10-31 | Emisphere Tech Inc | Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie |
| ES2327328T3 (es) | 2002-07-04 | 2009-10-28 | Zealand Pharma A/S | Glp-1 y procedimientos para el tratamiento de la diabetes. |
| WO2005014049A2 (en) | 2003-08-08 | 2005-02-17 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| PL2347762T3 (pl) | 2005-08-19 | 2019-09-30 | Amylin Pharmaceuticals, Llc | Eksendyna do leczenia cukrzycy i zmniejszania masy ciała |
| WO2007061434A2 (en) | 2005-11-10 | 2007-05-31 | Nastech Pharmaceutical Company Inc. | A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome |
| JP2009520693A (ja) | 2005-12-08 | 2009-05-28 | エムディーアールエヌエー，インコーポレイテッド | 安定化されたエキセンディン製剤の粘膜送達 |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| JP5021033B2 (ja) | 2006-09-07 | 2012-09-05 | エフ．ホフマン−ラ ロシュ アーゲー | Ｓｎａｃ（サルカプロザートナトリウム）の製造法 |
| CL2007002634A1 (es) * | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. |
| HUE029512T2 (en) | 2006-09-22 | 2017-03-28 | Novo Nordisk As | Protease Resistant Insulin Analogs |
| CN101868476B (zh) | 2007-09-05 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 胰高血糖素样肽-1衍生物及其制药用途 |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| RU2494755C2 (ru) | 2008-08-18 | 2013-10-10 | Интера Био Лтд. | Способы и композиции для перорального введения белков |
| EP2340049B1 (en) | 2008-09-12 | 2015-11-11 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| CN102869676A (zh) * | 2010-04-30 | 2013-01-09 | 株式会社三和化学研究所 | 用于提高生理活性物质等的生物体内稳定性的肽和提高了生物体内稳定性的生理活性物质 |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| PT2696687T (pt) * | 2011-04-12 | 2017-02-02 | Novo Nordisk As | Derivados de glp-1 duplamente acilados |
| JP6006309B2 (ja) * | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニーＡｍｙｌｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｌｃ | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| ES2690553T3 (es) * | 2012-03-22 | 2018-11-21 | Novo Nordisk A/S | Composiciones de péptidos GLP-1 y preparación de estas |
| JP6356660B2 (ja) | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー／エス | 送達剤を含む組成物およびその調製 |
| CN104487056A (zh) * | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | 包含肽和递送剂的片剂制剂 |
| MX369259B (es) | 2013-05-02 | 2019-11-04 | Novo Nordisk As | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
-
2014
- 2014-05-02 MX MX2015015009A patent/MX369259B/es active IP Right Grant
- 2014-05-02 JP JP2016511088A patent/JP6672140B2/ja active Active
- 2014-05-02 PT PT14721834T patent/PT2991671T/pt unknown
- 2014-05-02 KR KR1020187029869A patent/KR20180115814A/ko not_active Application Discontinuation
- 2014-05-02 EP EP18188817.3A patent/EP3485900A1/en active Pending
- 2014-05-02 EP EP14721834.1A patent/EP2991671B1/en not_active Revoked
- 2014-05-02 DK DK14721834.1T patent/DK2991671T3/en active
- 2014-05-02 CA CA2910903A patent/CA2910903A1/en not_active Withdrawn
- 2014-05-02 AU AU2014261336A patent/AU2014261336B2/en active Active
- 2014-05-02 WO PCT/EP2014/058974 patent/WO2014177683A1/en active Application Filing
- 2014-05-02 SI SI201430880T patent/SI2991671T1/sl unknown
- 2014-05-02 US US14/785,493 patent/US20160067184A1/en not_active Abandoned
- 2014-05-02 BR BR112015026325A patent/BR112015026325A2/pt not_active Application Discontinuation
- 2014-05-02 MY MYPI2015703259A patent/MY172578A/en unknown
- 2014-05-02 RS RS20181145A patent/RS58039B1/sr unknown
- 2014-05-02 HU HUE14721834A patent/HUE040609T2/hu unknown
- 2014-05-02 ES ES14721834.1T patent/ES2688462T3/es active Active
- 2014-05-02 KR KR1020157032843A patent/KR102272671B1/ko active IP Right Grant
- 2014-05-02 RU RU2015147876A patent/RU2671406C2/ru active
- 2014-05-02 LT LTEP14721834.1T patent/LT2991671T/lt unknown
- 2014-05-02 KR KR1020217020196A patent/KR20210086717A/ko not_active Application Discontinuation
- 2014-05-02 PL PL14721834T patent/PL2991671T3/pl unknown
-
2015
- 2015-09-24 IL IL241813A patent/IL241813A/en active IP Right Grant
- 2015-09-25 ZA ZA2015/07096A patent/ZA201507096B/en unknown
- 2015-10-27 MX MX2018012166A patent/MX2018012166A/es unknown
- 2015-10-27 MX MX2019013123A patent/MX2019013123A/es unknown
- 2015-10-29 SA SA515370075A patent/SA515370075B1/ar unknown
-
2017
- 2017-07-17 US US15/651,043 patent/US10278923B2/en active Active
-
2018
- 2018-08-29 HR HRP20181393TT patent/HRP20181393T1/hr unknown
- 2018-10-08 CY CY181101036T patent/CY1120730T1/el unknown
- 2018-10-12 ZA ZA2018/06791A patent/ZA201806791B/en unknown
-
2019
- 2019-03-22 US US16/361,971 patent/US20190216739A1/en active Pending
- 2019-12-25 JP JP2019235054A patent/JP2020073533A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| MX371187B (es) | Péptidos terapéuticos. | |
| PH12016501151A1 (en) | Nrf2 regulators | |
| HK1224178A1 (zh) | 環肽作為蛋白質靶向劑 | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| PH12016500598A1 (en) | Protoxin-ii variants and methods of use | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
| PH12016501183A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| PH12016501182A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| CY1119212T1 (el) | Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης | |
| IN2013MU03768A (es) | ||
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| IN2013CH00453A (es) | ||
| IN2013CH05769A (es) | ||
| IN2013CH05770A (es) | ||
| TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists | |
| HUP1300025A2 (hu) | Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak elõállítására és alkalmazása | |
| IN2013MU02732A (es) | ||
| GB201304675D0 (en) | Novel compositions having use in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GD | Licence granted |